Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 12/20 | 0.68 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.68 |
| ▸ | POLG | P54098 | 1/20 | 0.58 |
| ▸ | POLA1 | P09884 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2'-C-Methylcytidine Triphosphate SCHEMBL18561540 | 1.00 | P2RY2 (0.68) | P2RY2P2RY4POLGPOLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL18561539 | 1.00 | P2RY2 (0.68) | P2RY2P2RY4POLGPOLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL14853857 | 1.00 | P2RY2 (0.68) | P2RY2P2RY4POLGPOLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL14929178 | 1.00 | P2RY2 (0.68) | P2RY2P2RY4POLGPOLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL19537440 | 1.00 | P2RY2 (0.68) | P2RY2P2RY4POLGPOLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL14929175 | 1.00 | P2RY2 (0.68) | P2RY2P2RY4POLGPOLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL19537067 | 1.00 | P2RY2 (0.68) | P2RY2P2RY4POLGPOLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL21007902 | 1.00 | P2RY2 (0.68) | P2RY2P2RY4POLGPOLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL21006164 | 1.00 | P2RY2 (0.68) | P2RY2P2RY4POLGPOLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL19558282 | 1.00 | P2RY2 (0.68) | P2RY2P2RY4POLGPOLA1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084119-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2025-03-13 | — | — | US | disclosed |
| US-11981700-B2 | Pyrrolopyrimidine nucleosides and analogs thereof | CHIMERIX, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-20220002335-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2022-01-06 | — | — | US | disclosed |
| US-10941175-B2 | Pyrrolopyrimidine nucleosides and analogs thereof | CHIMERIX, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| EP-3331895-B1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF USEFUL AS ANTIVIRAL AGENTS | CHIMERIX INC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20200199167-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2020-06-25 | — | — | US | disclosed |
| US-10407457-B2 | Pyrrolopyrimidine nucleosides and analogs thereof | CHIMERIX, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3331895-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF USEFUL AS ANTIVIRAL AGENTS | Chimerix, Inc. (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-1525209-B1 | 1'-, 2'- AND 3' -MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170253628-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2017-09-07 | — | — | US | disclosed |
| US-20070060498-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | IDENIX (CAYMAN) LIMITED (KY) | 2007-03-15 | — | — | US | disclosed |
| US-20070042990-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-02-22 | — | — | US | disclosed |
| WO-2007022073-A2 | NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037735-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070015905-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
| EP-1536804-A2 | 2'-C-METHYL-3'-O-L-VALINE ESTER RIBOFURANOSYL CYTIDINE FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | Idenix (Cayman) Limited (KY) | 2005-06-08 | — | — | EP | disclosed |
| EP-1525209-A2 | 1'-, 2'- AND 3' -MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS | Idenix (Cayman) Limited (KY) | 2005-04-27 | — | — | EP | disclosed |
| US-20040077587-A1 | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004002422-A2 | 2’-C-METHYL-3’-O-L-VALINE ESTER RIBOFURANOSYL CYTIDINE FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | IDENIX (CAYMAN) LIMITED (KY) | 2004-01-08 | — | — | WO | disclosed |
| WO-2004003000-A2 | 1’-, 2'- AND 3'- MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX (CAYMAN) LIMITED (KY) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042990-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | PNP, NSUN2, HAVCR2 | P2RY2 331/4885P2RY4 296/4885POLG 1161/4885 |
| US-20070037735-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | PNP, NSUN2, HAVCR2 | P2RY2 331/4885P2RY4 296/4885POLG 1161/4885 |
| US-10407457-B2 | Pyrrolopyrimidine nucleosides and analogs thereof | TYMP, PNP, DPYD | P2RY2 634/4885P2RY4 375/4885POLG 289/4885 |
| US-20070060498-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | PNP, NSUN2, HAVCR2 | P2RY2 331/4885P2RY4 296/4885POLG 1161/4885 |
| US-20040077587-A1 | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | NSUN2, BCDIN3D, METTL16 | P2RY2 1718/4885P2RY4 2260/4885POLG 2388/4885 |
| US-20200199167-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | TYMP, PNP, DPYD | P2RY2 634/4885P2RY4 375/4885POLG 289/4885 |
| US-11981700-B2 | Pyrrolopyrimidine nucleosides and analogs thereof | TYMP, PNP, DPYD | P2RY2 634/4885P2RY4 375/4885POLG 289/4885 |
| US-20220002335-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | TYMP, PNP, DPYD | P2RY2 634/4885P2RY4 375/4885POLG 289/4885 |
| US-20170253628-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | TYMP, PNP, DPYD | P2RY2 634/4885P2RY4 375/4885POLG 289/4885 |
| US-20250084119-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | TYMP, PNP, DPYD | P2RY2 634/4885P2RY4 375/4885POLG 289/4885 |
| US-20070015905-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | PNP, NSUN2, HAVCR2 | P2RY2 331/4885P2RY4 296/4885POLG 1161/4885 |
| US-10941175-B2 | Pyrrolopyrimidine nucleosides and analogs thereof | TYMP, PNP, DPYD | P2RY2 634/4885P2RY4 375/4885POLG 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.